SPL receives FDA Special Protocol Assessment for BV Phase 3
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma to recoup $6 million cash for overseas R&D
- Starpharma signs cancer drug agreement with AstraZeneca
- Starpharma presenting at Bell Potter LifeScience Conference
- SPL docetaxel superior to Taxotere across multiple cancers
- Dendrimers improve anticancer efficacy lung metastasis model
Later from Starpharma
- Advances leading cancer therapeutic in drug delivery program
- GSK awarded funds for dermal treatment with SPL`s dendrimers
- SPL Commences VivaGel Bacterial Vaginosis Prevention Study
- SPL: Terminates Reckitt agreement and signs with Ansell
- Starpharma secures European (EMA) agreement on BV Phase 3
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma